Effects of DPP4 inhibitor, sitagliptin or Sulfonylurea on intrahepatic adipose mass and lipid metabolism in patients with type 2 diabetes accompanied by fatty liver : a prospective randomized, open-label trial

Trial Profile

Effects of DPP4 inhibitor, sitagliptin or Sulfonylurea on intrahepatic adipose mass and lipid metabolism in patients with type 2 diabetes accompanied by fatty liver : a prospective randomized, open-label trial

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Sitagliptin (Primary) ; Glimepiride
  • Indications Fatty liver; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Sep 2014 Status changed from active, no longer recruiting to completed, according to result presented at 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
    • 01 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top